Cristin-resultat-ID: 2053974
Sist endret: 23. januar 2023, 11:49
NVI-rapporteringsår: 2022
Resultat
Vitenskapelig artikkel
2022

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma

Bidragsytere:
  • Anand Khadse
  • Vilde Drageset Haakensen
  • Laxmi Silwal-Pandit
  • Julian Hamfjord
  • Patrick Micke
  • Johan Botling
  • mfl.

Tidsskrift

Frontiers in Oncology
ISSN 2234-943X
e-ISSN 2234-943X
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2022
Volum: 12
Open Access

Importkilder

Scopus-ID: 2-s2.0-85130171729

Beskrivelse Beskrivelse

Tittel

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma

Sammendrag

Lung cancer is a common disease with a poor prognosis. Genomic alterations involving the KRAS gene are common in lung carcinomas, although much is unknown about how different mutations, deletions, and expressions influence the disease course. The first approval of a KRAS-directed inhibitor was recently approved by the FDA. Mutations in the KRAS gene have been associated with poor prognosis for lung adenocarcinomas, but implications of the loss of heterozygosity (LOH) of KRAS have not been investigated. In this study, we have assessed the LOH of KRAS in early-stage lung adenocarcinoma by analyzing DNA copy number profiles and have investigated the effect on patient outcome in association with mRNA expression and somatic hotspot mutations. KRAS mutation was present in 36% of cases and was associated with elevated mRNA expression. LOH in KRAS was associated with a favorable prognosis, more prominently in KRAS mutated than in wild-type patients. The presence of both LOH and mutation in KRAS conferred a better prognosis than KRAS mutation alone. For wild-type tumors, no difference in prognosis was observed between patients with and without LOH in KRAS. Our study indicates that LOH in KRAS is an independent prognostic factor that may refine the existing prognostic groups of lung adenocarcinomas.

Bidragsytere

Anand Khadse

  • Tilknyttet:
    Forfatter
    ved Institutt for kreftforskning ved Oslo universitetssykehus HF
  • Tilknyttet:
    Forfatter
    ved Institutt for natur, helse og miljø ved Universitetet i Sørøst-Norge

Vilde Drageset Haakensen

  • Tilknyttet:
    Forfatter
    ved Seksjon for kreftgenetikk ved Oslo universitetssykehus HF
  • Tilknyttet:
    Forfatter
    ved Avdeling for kreftbehandling ved Oslo universitetssykehus HF

Laxmi Silwal-Pandit

  • Tilknyttet:
    Forfatter
    ved Seksjon for kreftgenetikk ved Oslo universitetssykehus HF

Julian Hamfjord

  • Tilknyttet:
    Forfatter
    ved Avdeling for kreftbehandling ved Oslo universitetssykehus HF
  • Tilknyttet:
    Forfatter
    ved Seksjon for kreftgenetikk ved Oslo universitetssykehus HF

Patrick Micke

  • Tilknyttet:
    Forfatter
    ved Uppsala universitet
1 - 5 av 10 | Neste | Siste »